The science of Tumor Treating Fields has the potential to extend beyond glioblastoma and mesothelioma. Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research spanning more than two decades. 

We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in more than 15 different solid tumor types in culture and in several in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our therapy to cancer patients who may benefit.

clinical pipeline
as of February 2024
CNS program
newly diagnosed glioblastoma
recurrent glioblastoma
thoracic cancer program
non-small cell lung cancer
abdominal cancer program

We also have pre-clinical data for Tumor Treating Fields in these areas:

breast cancer
cervical cancer
colorectal carcinoma
fibrous histiocytoma
malignant melanoma
renal adenocarcinoma
small cell lung cancer
urinary transitional cell carcinoma
uveal melanoma

clinical trials

We continue to test Tumor Treating Fields as a treatment for a broad range of solid tumors.

We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit and

clinical trial website

additional research

Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at

This information is for medical, and scientific and educational purposes only. Tumor Treating Fields therapy is experimental for the treatment of patients with brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Tumor Treating Fields therapy has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.